• Explore /
  • Poster
  • / Correlation of stable disease (SD) as best response with survival outcomes in patients (pts) with clear cell (cc) metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2).

Correlation of stable disease (SD) as best response with survival outcomes in patients (pts) with clear cell (cc) metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2).

Abstract Poster

Authors

Joseph Merriman

Joseph Merriman

University of Utah Huntsman Cancer Institute, Salt Lake City, UT

Joseph Merriman , Kinjal Parikh , Srinivas Kiran Tantravahi , Alli M. Straubhar , Archana M. Agarwal , Arun Sendilnathan , Joan Van Atta , Julia A. Batten , Kenneth F. Grossmann , Wolfram E. Samlowski , David D. Stenehjem , Neeraj Agarwal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer

Sub Track

Kidney Cancer

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 4577)

DOI

10.1200/jco.2014.32.15_suppl.4577

Abstract #

4577

Poster Bd #

145

Abstract Disclosures

Similar Posters

First Author: David D. Stenehjem

First Author: Suzanne Phillips

First Author: Joseph Clark

First Author: Giuseppe Procopio